Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of ABBV-932 Formulations in Healthy Adults
NCT06849791Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ABBV-932 (8 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration, Time to Cmax and 5 more. Started Feb 2025; status: completed.
02
Drugs
ABBV-932
Beyond the preview
Go deeper on NCT06849791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849791.